title: Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
abstract: The compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration was studied. Five milliliters of doxorubicin hydrochloride liposome injection 0.4 mg/mL in 5% dextrose injection was combined with 5 mL of each of 82 other drugs in 5% dextrose injection or, if necessary to avoid incompatibilities with the diluent, 0.9% sodium chloride injection. The combinations were examined with the unaided eye in fluorescent light and in high-intensity monodirectional light to enhance visualization of small particles and low-level turbidity. The turbidity of each combination was measured as well. Particle sizing and counting were performed on selected combinations. Evaluations were performed initially and at one and four hours. All combinations were stored at room temperature (approximately 23 degrees C). Most of the test drugs were compatible with doxorubicin hydrochloride liposome injection during the four-hour observation period. However, practitioners should be cautious in administering any drug simultaneously with doxorubicin hydrochloride liposome injection until the integrity of the liposomes can be verified. Eighteen drugs exhibited unacceptable increases or decreases in measured turbidity or particulate formation within four hours. During simulated Y-site administration, doxorubicin hydrochloride 0.4 mg/mL (as the liposomal injection) in 5% dextrose injection was compatible with 64 of 82 other drugs for four hours at approximately 23 degrees C and was incompatible with 18 of the test drugs.
authors.affiliation: Division of Pharmacy, University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.
authors.forename: L A
authors.initials: LA
authors.lastname: Trissel
authors.forename: D L
authors.initials: DL
authors.lastname: Gilbert
authors.forename: J F
authors.initials: JF
authors.lastname: Martinez
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000737:chemistry*; D004317:Doxorubicin / Q000008:administration & dosage / Q000737:chemistry*; D004344:Drug Incompatibility; D007262:Infusions, Intravenous; D008081:Liposomes
chemical_list: D000903:Antibiotics, Antineoplastic; D008081:Liposomes; D004317:Doxorubicin